EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Open Access · CC BY-NC 4.0

Clinical differences in sirolimus treatment with low target levels between children and adults with vascular malformations – A nationwide trial

Veroniek E M Harbers iD, Lilly G J M Zwerink, Gerard A Rongen, Willemijn M Klein, Carine J M van der Vleuten, Ingrid M P van Rijnsoever, Lynda Gerdsen-Drury, Uta E Flucke iD, Bas H Verhoeven, Peter C J de Laat, Chantal M A M van der Horst, Leo J Schultze Kool und 1 weitere

Clinical and Translational Science · 2023-05 · 16 (5) · 781-796

DOI: 10.1111/cts.13488 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Clinical and Translational Science, online erschienen am 23.02.2023. Verfasst von Veroniek E M Harbers und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Imaging, Radboud University Medical Center, Nijmegen, The Netherlands. Hauptthemen laut MEDLINE: Sirolimus, Vascular Malformations. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The clinical presentation of patients with slow‐flow vascular malformations is very heterogeneous. High clinical burden and subsequent reduced health‐related quality of life is something they have in common. There is an unmet medical need for these patients for whom regular treatments like surgery and embolization are either insufficient or technically impossible. Sirolimus has been reported to be effective and overall well‐tolerated in most patients. However, the main limitation of sirolimus is the reported high toxicity, especially when target levels of 10–15 ng/mL are being used. We report the results of a phase IIB single‐arm open‐label clinical trial consisting of 68 (67 in the challenge phase and 68 in the rechallenge phase) evaluable patients (children n = 33 and adults n = 35) demonstrating that treatment with low sirolimus target levels (4–10 ng/mL) is effective in 79.1% of the patients. When sirolimus treatment was stopped, the majority of patients experienced a recurrence of symptoms, supporting prolonged or even lifelong treatment requirement. Adults experienced a higher baseline pain score compared with children, having an estimated marginal mean of 6.2 versus 4.1, p < 0.05; however, they showed a similar decrease to children. Furthermore, the pediatric population experienced less often a sirolimus‐related grade I–IV adverse event (35.9% vs. 64.1%, p > 0.05) compared with adults. Additionally, response rates were higher in children compared with adults (93.8% vs. 65.7%, p < 0.05), and children responded faster (28 vs. 91 days, p < 0.05). These results suggest benefits of sirolimus in patients with slow‐flow vascular malformations and support its initiation as young as possible.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SirolimusVascular MalformationsAdultChildHumansQuality of LifeTreatment Outcome

Substanzen

Sirolimus

Autor:innen und Institutionen

  • Department of Medical Imaging, Radboud University Medical Center, Nijmegen, The Netherlands.
  • Radboudumc Center of Expertise HECOVAN, Amalia Children's Hospital, Radboud University Medical Center, Nijmegen, The Netherlands.
  • Department of Dermatology, Radboud University Medical Center, Nijmegen, The Netherlands.
  • Department of Internal Medicine and Pharmacology-Toxicology, Radboud University Medical Center, Nijmegen, The Netherlands.
  • VASCERN ERN on Rare Multisystemic Vascular Diseases, Healthcare Provider Coordinator: Assistance Publique-Hôpitaux de Paris, Hôpital Bichat-Claude Bernard, Centre de Réference (CRMR) Syndromes de Marfan et apparentés, P…
  • Department of Pediatrics, Amalia Children's Hospital, Radboud University Medical Center, Nijmegen, The Netherlands.

ORCID-Profile: Veroniek E M Harbers, Uta E Flucke

Zitieren

APA

Harbers, V. E. M., Zwerink, L. G. J. M., Rongen, G. A., Klein, W. M., van der Vleuten, C. J. M., van Rijnsoever, I. M. P., Gerdsen-Drury, L., Flucke, U. E., Verhoeven, B. H., de Laat, P. C. J., van der Horst, C. M. A. M., Schultze Kool, L. J., & Te Loo, D. M. W. M. (2023). Clinical differences in sirolimus treatment with low target levels between children and adults with vascular malformations – A nationwide trial. Clinical and Translational Science, 16(5), 781-796. https://doi.org/10.1111/cts.13488

Vancouver

Harbers VEM, Zwerink LGJM, Rongen GA, Klein WM, van der Vleuten CJM, van Rijnsoever IMP, et al. Clinical differences in sirolimus treatment with low target levels between children and adults with vascular malformations – A nationwide trial. Clinical and Translational Science. 2023;16(5):781-796. doi:10.1111/cts.13488

BibTeX
@article{Harbers2023,
  author = {Harbers, Veroniek E M and Zwerink, Lilly G J M and Rongen, Gerard A and Klein, Willemijn M and van der Vleuten, Carine J M and van Rijnsoever, Ingrid M P and Gerdsen-Drury, Lynda and Flucke, Uta E and Verhoeven, Bas H and de Laat, Peter C J and van der Horst, Chantal M A M and Schultze Kool, Leo J and Te Loo, D Maroeska W M},
  title = {Clinical differences in sirolimus treatment with low target levels between children and adults with vascular malformations – A nationwide trial},
  journal = {Clinical and Translational Science},
  year = {2023},
  volume = {16},
  number = {5},
  pages = {781--796},
  doi = {10.1111/cts.13488}
}
Kostenlos starten →